Miniere Hugo J M, Hormuth David A, Lima Ernesto A B F, Farhat Maguy, Panthi Bikash, Langshaw Holly, Shanker Mihir D, Talpur Wasif, Thrower Sara, Goldman Jodi, Ty Sophia, Chung Caroline, Yankeelov Thomas E
Departments of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin, TX, 78712, USA.
Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, 78712, USA.
BMC Cancer. 2025 Jul 29;25(1):1239. doi: 10.1186/s12885-025-14557-3.
High-grade gliomas are highly invasive and respond variably to chemoradiation. Accurate, patient-specific predictions of tumor response could enhance treatment planning. We present a novel computational platform that assimilates MRI data to continually predict spatiotemporal tumor changes during chemoradiotherapy.
Tumor growth and response to chemoradiation was described using a two-species reaction-diffusion model of enhancing and non-enhancing regions of the tumor. Two evaluation scenarios were used to test the predictive accuracy of this model. In scenario 1, the model was calibrated on a patient-specific basis (n = 21) to weekly MRI data during the course of chemoradiotherapy. A data assimilation framework was used to update model parameters with each new imaging visit which were then used to update model predictions. In scenario 2, we evaluated the predictive accuracy of the model when fewer data points are available by calibrating the same model using only the first two imaging visits and then predicted tumor response at the remaining five weeks of treatment. We investigated three approaches to assign model parameters for scenario 2: (1) predictions using only parameters estimated by fitting the data obtained from an individual patient's first two imaging visits, (2) predictions made by averaging the patient-specific parameters with the cohort-derived parameters, and (3) predictions using only cohort-derived parameters.
Scenario 1 achieved a median [range] concordance correlation coefficient (CCC) between the predicted and measured total tumor cell counts of 0.91 [0.84, 0.95], and a median [range] percent error in tumor volume of -2.6% [-19.7, 8.0%], demonstrating strong agreement throughout the course of treatment. For scenario 2, the three approaches yielded CCCs of: (1) 0.65 [0.51, 0.88], (2) 0.74 [0.70, 0.91], (3) 0.76 [0.73, 0.92] with significant differences between the approach (1) that does not use the cohort parameters and the two approaches (2 and 3) that do.
The proposed data assimilation framework enhances the accuracy of tumor growth forecasts by integrating patient-specific and cohort-based data. These findings show a practical method for identifying more personalized treatment strategies in high-grade glioma patients.
高级别胶质瘤具有高度侵袭性,对放化疗的反应各不相同。准确的、针对患者的肿瘤反应预测可以改进治疗方案规划。我们提出了一种新型计算平台,该平台可整合磁共振成像(MRI)数据,以持续预测放化疗期间肿瘤的时空变化。
使用肿瘤强化和非强化区域的双物种反应扩散模型来描述肿瘤生长及对放化疗的反应。采用两种评估方案来测试该模型的预测准确性。在方案1中,该模型针对每位患者(n = 21),根据放化疗过程中的每周MRI数据进行校准。使用数据同化框架,在每次新的成像检查时更新模型参数,然后用这些参数更新模型预测。在方案2中,我们通过仅使用前两次成像检查来校准同一模型,然后预测治疗剩余五周的肿瘤反应,从而评估在可用数据点较少时模型的预测准确性。我们研究了三种为方案2分配模型参数的方法:(1)仅使用通过拟合个体患者前两次成像检查获得的数据估计的参数进行预测,(2)通过将患者特定参数与队列衍生参数平均来进行预测,(3)仅使用队列衍生参数进行预测。
方案1在预测和测量的肿瘤总细胞数之间实现的中位数[范围]一致性相关系数(CCC)为0.91 [0.84, 0.95],肿瘤体积的中位数[范围]百分比误差为 -2.6% [-19.7, 8.0%],表明在整个治疗过程中具有很强的一致性。对于方案2,三种方法产生的CCC分别为:(1)0.65 [0.51, 0.88],(2)0.74 [0.70, 0.91],(3)0.76 [0.73, 0.92],不使用队列参数的方法(1)与使用队列参数的两种方法(2和3)之间存在显著差异。
所提出的数据同化框架通过整合患者特定数据和基于队列的数据提高了肿瘤生长预测的准确性。这些发现展示了一种在高级别胶质瘤患者中确定更个性化治疗策略的实用方法。